Drug Profile
Cannabidiol - Artelo Biosciences
Alternative Names: ART 1211; ART12.11; CBD CocrystalLatest Information Update: 09 Nov 2023
Price :
$50
*
At a glance
- Originator Artelo Biosciences
- Class Analgesics; Anti-inflammatories; Anti-ischaemics; Antiacnes; Antibacterials; Antiepileptic drugs; Antihyperglycaemics; Antihyperlipidaemics; Antineoplastics; Antiparkinsonians; Antipsoriatics; Antipsychotics; Antirheumatics; Anxiolytics; Behavioural disorder therapies; Cannabinoids; Cardiovascular therapies; Cyclohexenes; Drug withdrawal therapies; Heart failure therapies; Hepatoprotectants; Muscle relaxants; Neuroprotectants; Obesity therapies; Resorcinols; Skin disorder therapies; Small molecules
- Mechanism of Action Cannabinoid receptor CB1 inverse agonists; Cannabinoid receptor CB2 inverse agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer; Post-traumatic stress disorders
- Discontinued Inflammatory bowel diseases; Stroke
Most Recent Events
- 07 Nov 2023 Cannabidiol is still in preclinical trials for Post-traumatic stress disorders in USA prior to November 2023
- 28 Sep 2023 No recent reports of development identified for preclinical development in Post-traumatic-stress-disorders in USA (PO)
- 26 Jun 2023 Pharmacodynamics and pharmacokinetics data from preclinical trial in Post-traumatic stress disorders released by Artelo Biosciences